Novartis CEO: Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult…
Roche CEO laments Swiss franc strength, continues U.S. investment
Roche reported falling sales in the first three months of the year, as the strength of the Swiss…
Roche Q1 sales rise 6% CER, outlook confirmed
Roche (OTCQX: RHHBY) reported Group sales of CHF 14.7bn in Q1 2026: +6%…
Roche set to take its MS drug to regulators, but safety questions loom
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Readout Newsletter: Roche, Vertex, and J.D. Vance updates
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Defensive Giant At A Crossroads As Investors Weigh Pipeline Against Pricing Pressu
Roche’s stock has quietly slipped over the past days, even as analysts highlight a resilient pipeline and robust…
Roche to launch another Elevidys trial, hoping to win E.U. approval
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Anthropic appoints Novartis Chief Executive Officer to board
Anthropic has appointed Vas Narasimhan to its Board of Directors through the company’s Long-Term Benefit Trust. Narasimhan, a…
Swiss pharma firm Roche to acquire US-based biotech firm 89bio for $3.5B
Mucahithan Avcioglu September 18, 2025•Update: September 18, 2025 ISTANBUL Swiss pharmaceutical firm Roche has agreed to acquire US…
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
Novartis NOVN 1.69%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to…
Novartis shells out $2 billion for immunology biotech Excellergy
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus…
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals logo Recursion has merged Exscientia’s AI-driven chemistry with its own phenomics and a new ClinTech real-world-data…